<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860063</url>
  </required_header>
  <id_info>
    <org_study_id>MeSHIV-001</org_study_id>
    <nct_id>NCT04860063</nct_id>
  </id_info>
  <brief_title>Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.</brief_title>
  <acronym>BERMESyH</acronym>
  <official_title>Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in People Living With HIV.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Civil de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Civil de Guadalajara</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      With current antiretroviral therapy, people living with HIV reach virological suppression&#xD;
      faster, which in turn leads to a higher life expectancy. Nevertheless, this improved survival&#xD;
      rate is not free of other comorbidities, such as metabolic syndrome, characterized by a&#xD;
      decrease in glucose tolerance and an increase in insulin resistance.&#xD;
&#xD;
      Berberine is an alkaloid that has proven beneficial effects on both glucose tolerance and&#xD;
      insulin resistance, but has not been tested in people living with HIV under virological&#xD;
      suppression. We hypothesize that berberine will improve inflammatory markers and metabolic&#xD;
      profile in this population without significant interactions nor adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>24 weeks within randomization</time_frame>
    <description>Change from Baseline insulin resistance determined by Homeostasis Model Assessment index, triglyceride to glucose ratio, at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline lipid profile at 6 months</measure>
    <time_frame>At the beginning and 24 weeks within randomization</time_frame>
    <description>Measurement of total cholesterol, HDL, LDL, triglycerides.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline weight</measure>
    <time_frame>At the beginning and 24 weeks within randomization</time_frame>
    <description>Weight gain or loss measure by kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory profile</measure>
    <time_frame>At the beginning and 24 weeks within randomization</time_frame>
    <description>Level of pro-inflammatory cytokines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>HIV-1-infection</condition>
  <condition>Glucose Intolerance</condition>
  <condition>Dyslipidemias</condition>
  <condition>Lipodystrophy</condition>
  <condition>Lipoatrophy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo three times daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine 500 mg three times daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months</description>
    <arm_group_label>Berberine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 60 years&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  Stable antiretroviral therapy at least 6 months before enrollment&#xD;
&#xD;
          -  Viral suppression&#xD;
&#xD;
          -  Metabolic syndrome , defined by Adult Treatment Panel-III criteria&#xD;
&#xD;
          -  No previously known kidney or liver disease&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People younger than 18 years and older than 60 years&#xD;
&#xD;
          -  Prior atherosclerotic cardiovascular disease&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2&#xD;
&#xD;
          -  Previous use of glucose and/or lipid modifying medications&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Withdrawal of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 17, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Civil de Guadalajara</investigator_affiliation>
    <investigator_full_name>Sha√∫l Ariel Navarro Lara</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

